Pharmaceuticals News and Research

RSS

Scientists discover the secrets of NF-kappaB

A study published in Science examines a key player in conditions such as cancer, inflammatory bowel disease, rheumatoid arthritis and asthma and has shown that cells use a sophisticated communication system to coordinate responses to infection and maintain inflammation in the body.

12 Apr 2009

Serentis begins trial with first-in-class SRD441 for eczema

Serentis, a privately owned biopharmaceutical company, announced that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema.

9 Apr 2009

Research could lead to new non-antibiotic drugs to counter hospital infections

Lack of an adequate amount of the mineral phosphate can turn a common bacterium into a killer, according to research to be published in the April 14, 2009, issue of the Proceedings of the National Academies of Science.

9 Apr 2009

Johns Hopkins tightens rules on industry interactions

Johns Hopkins Medicine has adopted a new policy that significantly limits interactions with industry while ensuring effective, principled and appropriate partnerships with drug and medical device makers.

9 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

Cancer vaccines receive orphan drug designation for advanced head and neck cancer

Two experimental vaccines from the University of Maryland, Baltimore (UMB) recently received a federal orphan drug designation for advanced head and neck cancer, according to a company official.

9 Apr 2009

Coartem tablets approved in U.S. to treat malaria

The U.S. Food and Drug Administration has approved Coartem tablets (artemether and lumefantrine) for the treatment of acute, uncomplicated malaria infections in adults and children weighing at least five kilograms (approximately 11 pounds).

8 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

New nanostructured biosensors

Research and industry are increasingly exploiting the potential of aptamers.

8 Apr 2009

Reovirus kills cancer stem cells

Dalhousie Medical School cancer researcher Dr. Patrick Lee has proven that a common virus can infect and kill breast cancer stem cells.

8 Apr 2009

Major health care overhaul in China

Chinese officials have unveiled a health-care plan which promises to deliver to all its 1.3 billion citizens, fair and affordable health services by the year 2020.

8 Apr 2009

Stem cells from bone marrow used to grow new blood vessels

Research led by David Hess of the Robarts Research Institute at The University of Western Ontario has identified how to use selected stem cells from bone marrow to grow new blood vessels to treat diseases such as peripheral artery disease.

6 Apr 2009

Gilead Sciences announces notification of ANDA filing for Atripla

Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.

6 Apr 2009

Dietary flaxseed may help prevent colorectal tumors

New research from South Dakota State University offers evidence that including flax in the diet may help prevent colorectal tumors or keep tumors from growing as quickly when they do form.

6 Apr 2009

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

AVEO Pharmaceuticals, Inc. has announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.

6 Apr 2009

FDA warns 14 pharmaceutical companies about short internet ads lacking risk information

FDA has warned 14 major pharmaceutical firms about brief Internet advertisements that could have misled patients because they did not include information about health risks related to the drugs, according to letters posted to the agency's Web site Friday, the Wall Street Journal reports.

6 Apr 2009

Zosano Pharma presents positive results for needle-free osteoporosis therapy

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, has presented positive results from its phase 2 study of the ZP-PTH rapid delivery patch for the treatment of osteoporosis at the 8th International Symposium on Osteoporosis in Washington, D.C.

6 Apr 2009

Researcher tackles deadly brain tumors

Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically.

6 Apr 2009

Taro receives final FDA approval for Carbamazepine extended-release tablets

Taro Pharmaceutical Industries Ltd. has reported that it received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application ("ANDA") for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg and 400 mg ("carbamazepine extended-release tablets").

6 Apr 2009